Pay Here Now

Lowcountry Infectious Diseases
Lowcountry Infectious Diseases
  • Home
  • Our Team
  • Jobs
  • Patient Info
  • Infusion Center
  • Research
  • ID
  • Contact Us
  • More
    • Home
    • Our Team
    • Jobs
    • Patient Info
    • Infusion Center
    • Research
    • ID
    • Contact Us
  • Home
  • Our Team
  • Jobs
  • Patient Info
  • Infusion Center
  • Research
  • ID
  • Contact Us
About us

Research

Lowcountry Infectious Diseases conducts clinical research and provides novel pharmaceutical therapies for many types of infectious diseases. The clinical research trials are conducted in our office or hospital setting to provide volunteers with access to treatment options that may not be available to the public.

Our Team & You

Our Principal Investigator, Dr. Kent Stock, has been performing infectious disease research for over 30 years and personally oversees all clinical trial patients.  He has managed clinical trials for the treatment of HIV/AIDS, gastrointestinal infections, upper and lower respiratory infections and many other conditions.  If you are interested in learning more about our clinical research, our experienced research team can review your medical history with you to determine eligibility and answer all your questions.


Ask your Lowcountry ID provider if one of the following trials could benefit you.


Or for information on non-treatment studies, contact our research team:

Christine Horne, Director of Research, chorne@lcids.com, 843.212.8693

Compensation may be provided to those who qualify!

Our Clinical Trials

Nontuberculous Mycobacterial (NTM) Lung Infection caused by Mycobacterium Avium Complex (MAC)

ENCORE - A randomized, double-blind, placebo-controlled, active comparator, multicenter study to evaluate the efficacy and safety of an Amikacin Liposome Inhalation Suspension (ALIS)-based regimen in adult subjects with newly diagnosed nontuberculous mycobacterial (NTM) lung infection caused by mycobacterium avium complex (MAC).

Pulmonary Nontuberculous Mycobacterial Infection

A randomized, double-blind, placebo-controlled phase 2/3 study of the efficacy and safety of treatment with MNKD-101 (Clofazimine Inhalation Suspension) in combination with guideline-based therapy in patients with pulmonary nontuberculous mycobacterial infection followed by an open-label extension.

Recurrent Clostridioides Difficile Infection

A randomized, double-blind, placebo-controlled phase 3 study of VE303 for prevention of recurrent clostridioides difficile infection.


Copyright © 2025 Lowcountry Infectious Diseases - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept

Clinical Trial Opportunity

Please contact Christine at 843.212.8693 for information on non-treatment studies.  Compensation may be provided to those who qualify.